GRPH
Closed
Graphite Bio Inc
22.26
-27.74 (-55.48%)
Last Update: 22 Mar 2024 16:30:00
Yesterday: 50.
Day's Range: 22.26 - 22.26
Send
sign up or login to leave a comment!
When Written:
2.45
Graphite Bio Inc. is a biotechnology company that focuses on developing gene editing therapies for patients with serious genetic diseases. The company is based in Boston, Massachusetts, and was founded in 2018 by a team of experienced biotech executives and scientists. Graphite Bio's technology platform is based on the use of CRISPR/Cas9 gene editing to correct genetic mutations that cause diseases such as sickle cell anemia and beta-thalassemia. The company has raised over $150 million in funding from investors, including GV, Versant Ventures, and Samsara BioCapital. Graphite Bio is currently conducting preclinical studies and expects to begin clinical trials in the near future.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








